EBD GmbH is part of the Knowledge & Networking Division of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
BioPharm America 2014 EBD Group MassBio

Share/Follow Us

Share this:
Follow this event:
Follow us on Twitter
Subscribe to our newsletters:

BioPharm America™ 2015 Press Releases

July 22, 2015BioPharm America™ 2015 to bring industry heavy hitters and biotech disruptors to Boston September 15–17 BioPharm America 2015 will once again bring the most talented, innovative leaders of biotech and pharma to Boston this September 15–17 at the Boston Marriott Copley Place. An increasing number of industry heavy hitters have successfully led and exited large corporations and are now investing their experience, clout and personal finances to reseed the life science ecosy...  more ►

June 9, 2015Spotlight on Boston Business Facts The life sciences corridor in Massachusetts combines the cities of Somerville, Cambridge, Boston, Quincy and Braintree, and is home to over 450 companies within the life science industry cluster. There were USD 1,802 billion of venture investments in Massachusetts biotechs in 2014. Massachusetts has seen 30 companies go public in the last two years. Some of the largest bio...  more ►

May 20, 2015Engage and De-Risk: BioPharm America™ 2015 draws life science dealmaking ecosystem to Boston this September 15–17 EBD Group and MassBio present the eighth annual BioPharm America international life science partnering conference September 15–17 at Boston Marriott Copley Place in the center of Boston's historic Back Bay. The event brings executives from the life science ecosystem together to de-risk the environment inherent to biotech and engage in disruptive dealmaking. BioPharm Am...  more ►



partnering360:Insight Latest headlines from partnering360:Insight

July 21, 2015 Patient-centric Baxalta capitalizes on Cambridge When Baxalta Incorporated spun out of Baxter on July 1, it already qualified as "big pharma." With USD 6 billion in annual revenues, 16,000 employees, operations in 100 countries and USD 600 million invested in R&D, it focuses its assets tightly on the patient experience and expects its partners to do the same. more ►

June 12, 2015 Boehringer Ingelheim Pharmaceuticals: “The world is our laboratory” At Boehringer Ingelheim, “innovation is the element that defines us,” said Paola Casarosa, PhD, Corporate VP, Business Development and Licensing (BD&L)/Prescription Medicines. Its track record bears that out. Boehringer Ingelheim has a 125-year history of innovation that is based not only on its own discoveries but also upon novel finds from partners throughout the life sciences. more ►

June 11, 2015 Boston Children’s Hospital: Innovating from bench to bedside Translating innovation from the bench to the bedside is integral to the mission of Boston Children’s Hospital. Research runs the gamut from biotech and pharmaceutical development to devices, diagnostics and healthcare IT, and is led by researchers who often are appointed not just to Boston Children’s Hospital, but also to prestigious institutions in the area. more ►

June 3, 2015 Agilis builds value by tapping into Boston’s biotech ecosystem In November 2014, Gregory Robinson was named the Chief Scientific Officer for Agilis Biotherapeutics, a biotechnology company engineering best-in-class DNA therapeutics for patients afflicted with devastating rare diseases of the central nervous system (CNS). Formerly the Senior Director for Rare Diseases Business Development and the Head of Discovery Research at Shire, Robinson has stepped up to the challenge of advancing Agilis’ drug and therapy discovery programs. more ►

June 3, 2015 When de-risking, relationships matter De-risking has evolved from literature searches to the cultivation of many wide-ranging relationships throughout the life sciences strata. “In the ‘old’ days, you’d look for others working with the same mechanism or against the same targets and hope their data lent confidence to your own investigations as you followed in their wake,” says Richard Brudnick senior VP, corporate development, Biogen, says. That approach reduced risk, but didn’t encourage great innovation. more ►



Arrow Up


 
 

Follow this event: Follow us on Twitter
Sign up now
For news and updates

Privacy Policy and Cookies Terms of Use

See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2015 EBD Group, Inc.
Privacy Policy and Cookies
Terms of Use